The present invention provides cannabinoid derivatives, a pharmaceutical composition comprising said derivative and a method of using said derivatives in treating or preventing a disease associated with cannabinoid receptors. The claimed cannabinoid derivatives are described by formula (I) or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound.

The present invention provides cannabinoid derivatives, a pharmaceutical composition comprising said derivative and a method of using said derivatives in treating or preventing a disease associated with cannabinoid receptors. The claimed cannabinoid derivatives are described by formula (I) or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound.

An organic electroluminescent element that uses a compound expressed by the following general formula emits dark blue light and exhibits little change in chromaticity during brightness modulation. (n1 is an integer from 0 to 8; the R.sup.1 [groups] are each independently a substituent substituted for a hydrogen atom of the pyrene skeleton; X is CR.sup.aR.sup.b (R.sup.a and R.sup.b are each independently a hydrogen atom or a substituent), O, S, or SiR.sup.dR.sup.e (R.sup.d and R.sup.e are each independently a hydrogen atom or a substituent); and A.sup.1 to A.sup.4 represent each independently either N or CR.sup.f (R.sup.f represents a hydrogen atom or a substituent, and two adjacent R.sup.f [groups] may jointly form a saturated or unsaturated ring, but no more than two rings may be formed jointly by two or more of the R.sup.f [groups]).)

An organic electroluminescent element that uses a compound expressed by the following general formula emits dark blue light and exhibits little change in chromaticity during brightness modulation. (n1 is an integer from 0 to 8; the R.sup.1 [groups] are each independently a substituent substituted for a hydrogen atom of the pyrene skeleton; X is CR.sup.aR.sup.b (R.sup.a and R.sup.b are each independently a hydrogen atom or a substituent), O, S, or SiR.sup.dR.sup.e (R.sup.d and R.sup.e are each independently a hydrogen atom or a substituent); and A.sup.1 to A.sup.4 represent each independently either N or CR.sup.f (R.sup.f represents a hydrogen atom or a substituent, and two adjacent R.sup.f [groups] may jointly form a saturated or unsaturated ring, but no more than two rings may be formed jointly by two or more of the R.sup.f [groups]).)